ABVC BioPharma (ABVC) has had the highest return since January 1, 2025 by a US stock with an IPO date in 2017, returning 415.3%.
| ASSET | % RETURN |
|---|---|
ABVC BioPharma (ABVC) | 415.25% |
ImmunoPrecise Antibodies (HYFT) | 326.83% |
Caledonia Mining (CMCL) | 287.71% |
Celcuity LLC (CELC) | 273.68% |
Metalpha Technology (MATH) | 227.68% |
Ramaco Resources (METC) | 226.58% |
Fubotv (FUBO) | 219.23% |
AquaBounty Technologies (AQB) | 213.29% |
American Resources Corp Class A (AREC) | 200% |
National Vision (EYE) | 176.94% |
Acm Research (ACMR) | 157.26% |
Metalla Royalty & Streaming (MTA) | 150% |
Verona Pharma PLC ADR (VRNA) | 128.4% |
AnaptysBio (ANAB) | 128.17% |
New Pacific Metals (NEWP) | 127.73% |
Standard Lithium (SLI) | 126.17% |
Skeena Resources (SKE) | 107.55% |
NCS Multistage (NCSM) | 91.02% |
Carvana (CVNA) | 87.96% |
UroGen Pharma (URGN) | 84.72% |
Spero Therapeutics (SPRO) | 79.05% |
Nouveau Monde Graphite (NMG) | 77.5% |
Rev (REVG) | 77% |
Rhythm Pharmaceuticals (RYTM) | 76.12% |
Laureate Education (LAUR) | 73.2% |
